4.6 Article

Regulation of the transforming growth factor β pathway by reversible ubiquitylation

期刊

OPEN BIOLOGY
卷 2, 期 -, 页码 -

出版社

ROYAL SOC
DOI: 10.1098/rsob.120082

关键词

transforming growth factor; ubiquitylation; ubiquitination; deubiquitylation; DUBs; ubiquitin

资金

  1. Medical Research Council UK
  2. AstraZeneca
  3. Boehringer-Ingelheim
  4. GlaxoSmithKline
  5. Merck-Serono
  6. Pfizer
  7. Johnson Johnson
  8. Medical Research Council [MC_U127092717] Funding Source: researchfish
  9. MRC [MC_U127092717] Funding Source: UKRI

向作者/读者索取更多资源

The transforming growth factor beta (TGF beta) signalling pathway plays a central role during embryonic development and in adult tissue homeostasis. It regulates gene transcription through a signalling cascade from cell surface receptors to intracellular SMAD transcription factors and their nuclear cofactors. The extent, duration and potency of signalling in response to TGF beta cytokines are intricately regulated by complex biochemical processes. The corruption of these regulatory processes results in aberrant TGF beta signalling and leads to numerous human diseases, including cancer. Reversible ubiquitylation of pathway components is a key regulatory process that plays a critical role in ensuring a balanced response to TGF beta signals. Many studies have investigated the mechanisms by which various E3 ubiquitin ligases regulate the turnover and activity of TGF beta pathway components by ubiquitylation. Moreover, recent studies have shed new light into their regulation by deubiquitylating enzymes. In this report, we provide an overview of current understanding of the regulation of TGF beta signalling by E3 ubiquitin ligases and deubiquitylases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据